Brief: Bolt Biotherapeutics Receives Orphan Drug Designation For BDC-1001 For Treatment Of Gastric Cancers
28/09/2023 12:05
Sept 28 (Reuters) - Bolt Biotherapeutics Inc BOLT.O :
* BOLT BIOTHERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FOR
BDC-1001 FOR TREATMENT OF GASTRIC CANCERS
* BOLT BIOTHERAPEUTICS INC - FDA GRANTED BDC-1001 ORPHAN
DRUG
DESIGNATION FOR TREATMENT OF GASTRIC CANCER, INCLUDING
GASTROESOPHAGEAL JUNCTION CANCER
Source text for Eikon: ID:nGNX2g6Wks
Further company coverage: BOLT.O
((reuters.briefs@thomsonreuters.com;))